0000000001169824

AUTHOR

Francesco Carubbi

showing 41 related works from this author

Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing ma…

2015

In this paper, we aimed to evaluate the levels of ferritin enriched in H subunits (H-ferritin) and ferritin enriched in L subunits (L-ferritin) and the cells expressing these 2 molecules, in the bone marrow (BM) and liver biopsies obtained from adult onset Still's disease (AOSD) patients who developed macrophage activation syndrome (MAS), and correlating these data with the severity of the disease. Twenty-one patients with MAS-associated AOSD underwent BM biopsy and among them, 9 patients with hepatomegaly and elevated liver enzymes underwent liver biopsy. All the samples were stained by both immunohistochemistry and immunofluorescence. A statistical analysis was performed to estimate the p…

Adult-OnsetAdultPathologymedicine.medical_specialtyApoferritinImmunologyAdult-onset Still's disease; Hyperferritinemia; Macrophage activation syndrome; Adult; Age of Onset; Animals; Apoferritins; Bone Marrow; Humans; Liver; Macrophage Activation Syndrome; Still's Disease Adult-Onset; Immunology; Immunology and Allergy; Medicine (all)ImmunofluorescenceAdult-onset Still's diseaseBone MarrowBiopsymedicineAnimalsHumansImmunology and AllergyAge of Onsetmedicine.diagnostic_testbiologyCD68business.industryAnimalMacrophage Activation SyndromeMedicine (all)medicine.diseaseStill's DiseaseFerritinmedicine.anatomical_structureLiverMacrophage activation syndromeLiver biopsyApoferritinsbiology.proteinImmunohistochemistryBone marrowHyperferritinemiabusinessStill's Disease Adult-OnsetHuman
researchProduct

Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling

2019

AbstractSystemic Sclerosis (SSc) is a disease with limited therapeutic possibilities. Mesenchymal stem cells (MSCs)-therapy could be a promising therapeutic option, however the ideal MSCs source has not yet been found. To address this problem, we perform comparison between bone marrow (BM)-MSCs and adipose (A)-MSCs, by the miRs expression profile, to identify the gene modulation in these two MSCs source. MicroRNAs (miRs) are RNAs sequences, regulating gene expression and MSCs, derived from different tissues, may differently respond to the SSc microenvironment. The miRs array was used for the miRs profiling and by DIANA-mirPath tool we identified the biological functions of the dysregulated …

Adult0301 basic medicineTherapeutic gene modulationAutoimmune diseasesCellular differentiationGene regulatory networklcsh:MedicineBone Marrow CellsBiologyRegenerative medicineArticle03 medical and health sciences0302 clinical medicinemicroRNAmedicineHumansGene Regulatory Networkslcsh:ScienceCells CulturedSystemic SclerosiCell ProliferationRegulation of gene expressionScleroderma SystemicMultidisciplinarySequence Analysis RNAGene Expression ProfilingMesenchymal stem celllcsh:RCell DifferentiationMesenchymal Stem CellsSettore MED/16 - ReumatologiaMicroRNAs030104 developmental biologymedicine.anatomical_structureAdipose TissueGene Expression RegulationCancer researchSystemic sclerosisFemalelcsh:QBone marrow030217 neurology & neurosurgeryScientific Reports
researchProduct

H-ferritin and CD68+/H-ferritin+ monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi…

2016

Summary Adult-onset Still's disease (AOSD) patients may show an evanescent salmon-pink erythema appearing during febrile attacks and reducing without fever. Some patients may experience this eruption for many weeks. During AOSD, exceptionally high serum levels of ferritin may be observed; it is an iron storage protein composed of 24 subunits, heavy (H) subunits and light (L) subunits. The ferritin enriched in L subunits (L-ferritin) and the ferritin enriched in H subunits (H-ferritin) may be observed in different tissues. In this work, we aimed to investigate the skin expression of both H-and L-ferritin and the number of macrophages expressing these molecules from AOSD patients with persist…

Male0301 basic medicinePathologymedicine.medical_specialtyAdult-onset Still's diseaseDermal immune systemErythemaMacrophageBiopsyImmunologyAntigens Differentiation MyelomonocyticGene ExpressionDiseaseAdult-onset Still's diseaseMonocytesH-Ferritin03 medical and health sciences0302 clinical medicineAntigens CDadult-onset Still's disease; dermal immune system; ferritin; hyperferritinaemic syndrome; macrophagemedicineHumansImmunology and AllergyMonocytes macrophagesMacrophageRNA MessengerSkin030203 arthritis & rheumatologyFerritinbiologyCD68MacrophagesOriginal ArticlesFerritinSettore MED/16 - Reumatologia030104 developmental biologyApoferritinsImmunologyLeukocytes Mononuclearbiology.proteinCytokinesFemaleInflammation Mediatorsmedicine.symptomHyperferritinaemic syndromeStill's Disease Adult-OnsetBiomarkersClinical and Experimental Immunology
researchProduct

Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry

2022

ObjectiveFibromyalgia (FM) is a chronic musculoskeletal pain syndrome of unknown aetiopathogenesis. Its development and maintenance are related to the interplay of biological, psychological, and contextual factors. Among the contextual factors, sociodemographic aspects are poorly elucidated. This study aimed to evaluate the relationships between sociodemographic/ clinical factors and symptom severity measures using a web-based registry of patients with FM.MethodsAdult patients with an ACR 2010/2011 diagnosis of FM underwent a clinical evaluation and were asked to complete questionnaires covering their sociodemographic data (gender, age, marital status, educational level), and disease-specif…

AdultMalesociodemographic factorsImmunologyReproducibility of ResultsSeverity of Illness IndexRheumatologysociodemographic factors.Surveys and QuestionnairesQuality of LifegenderImmunology and AllergyHumansFemalefibromyalgiaRegistriesChronic Painadult; female; humans; male; quality of life; registries; reproducibility of results; severity of illness index; sociodemographic factors; surveys and questionnaires; chronic pain; fibromyalgia
researchProduct

Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and De…

2016

Objective.Microvascular damage is pivotal in the pathogenesis of systemic sclerosis (SSc), preceding fibrosis, and whose trigger is not still fully understood. Perivascular progenitor cells, with profibrotic activity and function, are identified by the expression of the isoform 12 of ADAM (ADAM12) and this molecule may be upregulated by transforming growth factor-β (TGF-β). The goal of this work was to evaluate whether pericytes in the skin of patients with diffuse cutaneous SSc (dcSSc) expressed ADAM12, suggesting their potential contribution to the fibrotic process, and whether TGF-β might modulate this molecule.Methods.After ethical approval, mesenchymal stem cells (MSC) and fibroblasts …

0301 basic medicineAdultMalePathologymedicine.medical_specialtyImmunologyADAM12 Protein03 medical and health sciencesYoung AdultRheumatologyFibrosisTransforming Growth Factor betamedicineImmunology and AllergyHumansProgenitor cellMyofibroblastsSkinintegumentary systembusiness.industryMedicine (all)FIBROSIS; PERICYTE; SYSTEMIC SCLEROSIS; Rheumatology; Immunology; Immunology and AllergyMesenchymal stem cellTransdifferentiationMesenchymal Stem CellsMiddle Agedmedicine.diseaseFibrosisActinsUp-RegulationSettore MED/16 - Reumatologia030104 developmental biologymedicine.anatomical_structurePERICYTEFIBROSIS; PERICYTE; SYSTEMIC SCLEROSIS; Immunology and Allergy; Rheumatology; Immunology; Medicine (all)SYSTEMIC SCLEROSISCell TransdifferentiationScleroderma DiffuseFemalePericyteBone marrowbusinessPericytesMyofibroblastTransforming growth factorThe Journal of rheumatology
researchProduct

Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleot…

2015

Summary A better understanding about the mechanisms involved in the pathogenesis of type 2 diabetes mellitus (T2D) showed that inflammatory cytokines such as tumour necrosis factor (TNF) and interleukin (IL)-1β play a pivotal role, mirroring data largely reported in rheumatoid arthritis (RA). IL-1β is produced mainly by monocytes (MO), and hyperglycaemia may be able to modulate, in the cytoplasm of these cells, the assembly of a nucleotide-binding domain and leucine-rich repeat containing family pyrin (NLRP3)-inflammosome, a cytosolic multi-protein platform where the inactive pro-IL-1β is cleaved into active form, via caspase-1 activity. In this paper, we evaluated the production of IL-1 β …

Maletype 2 diabetes mellituInflammasomesMessengerIL-1β; NLRP3-inflammasome; rheumatoid arthritis; type 2 diabetes mellitus; Adult; Arthritis Rheumatoid; Carrier Proteins; Caspase 1; Cells Cultured; Diabetes Mellitus Type 2; Enzyme Activation; Female; Glucose; Humans; Hyperglycemia; Inflammasomes; Inflammation; Interleukin-1beta; Leukocytes Mononuclear; Male; Middle Aged; RNA Messenger; Tumor Necrosis Factor-alphaInterleukin-1betaArthritisPyrin domainInflammasomeArthritis RheumatoidRheumatoidImmunology and AllergyCells CulturedCulturedCaspase 1InterleukinDiabetes MellituMiddle AgedIL-1βTumor necrosis factor alphaNLRP3-inflammasomeFemalemedicine.symptomType 2ArthritiHumanAdultmedicine.medical_specialtyMononuclearImmunologyCaspase 1InflammationProinflammatory cytokineInternal medicineNLR Family Pyrin Domain-Containing 3 ProteinmedicineHumansRNA MessengerInflammationbusiness.industryTumor Necrosis Factor-alphaType 2 Diabetes MellitusOriginal Articlesrheumatoid arthritiLeukocytemedicine.diseaseEnzyme ActivationEndocrinologyGlucoseDiabetes Mellitus Type 2HyperglycemiaImmunologyLeukocytes MononuclearRNACellbusinessCarrier ProteinsCarrier Protein
researchProduct

OP0081 Aberrant Expression of IL-22RA1 on Hematopoietic Cells as Immunologically Signature of Primary Sjogren’s Syndrome and Sjogren-Associated Non-H…

2013

Background Interleukin (IL)-22 is a potent mediator of cellular inflammatory responses that has been recently reported to play a role in the pathogenesis of primary Sjogren’s Syndrome (p-SS) (1, 2) and of T and B lymphomas. IL-22 biological activity is initiated by binding to a cell-surface complex composed of two subunits, IL-22R1 and IL-10R2 receptor chains, and further regulated by interactions with a soluble binding protein, IL-22BP. Unlike the IL-10R2, which is constitutively expressed in many human tissues, IL-22R1 is not detectable in immune cells. Objectives Aim of this study was to better characterize the role of IL-22 axis in the pathogenesis of p-SS and p-SS-associated lymphomas.…

business.industryCD68ImmunologyInterleukinmedicine.diseasePeripheral blood mononuclear cellGeneral Biochemistry Genetics and Molecular BiologyLymphomaInterleukin 22PathogenesisHaematopoiesisImmune systemRheumatologyImmunologyCancer researchImmunology and AllergyMedicinebusinessAnnals of the Rheumatic Diseases
researchProduct

Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.

2015

Summary The aim of this study was to elucidate more clearly the role of interleukin (IL)-18 in modulating the IL-22 pathway in primary Sjögren's syndrome (pSS) patients and in pSS-associated lymphomas. Minor salivary glands (MSGs) from patients with pSS and non-specific chronic sialoadenitis (nSCS), parotid glands biopsies from non-Hodgkin lymphomas (NHL) developed in pSS patients, were evaluated for IL-18, IL-22, IL-22 receptor 1 (IL-22R1), IL-22 binding protein (IL-22BP) and signal transducer and activator of transcription-3 (STAT-3) expression. MSGs IL-22R1-expressing cells were characterized by confocal microscopy and flow cytometry in pSS, nSCS and healthy controls. The effect of recom…

MaleSalivary Glandslaw.inventionInterleukin 22lawIL-22Immunology and AllergyMyeloid CellsIL-22R1Receptormedicine.diagnostic_testnon-Hodgkin lymphomaLymphoma Non-HodgkinInterleukin-17TranslationalInterleukin-18Lacrimal ApparatusInterleukinMiddle AgedHaematopoiesisSjogren's SyndromeIL-22BPRecombinant DNASjögren's syndromeInterleukin 18FemaleIL-18Signal TransductionAdultSTAT3 Transcription FactorImmunologyPrimary Cell CultureBiologyPeripheral blood mononuclear cellIL-18; IL-22; IL-22BP; IL-22R1; Sjögren's syndrome; non-Hodgkin lymphomaSialadenitisFlow cytometrystomatognathic systemmedicineHumansAgedInterleukinsMacrophagesReceptors InterleukinSettore MED/16 - Reumatologiastomatognathic diseasesGene Expression RegulationImmunologyLeukocytes MononuclearClinical and experimental immunology
researchProduct

The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients

2021

Abstract Objective Various studies have shown that overweight and obesity are central features of FM, but the real impact of a high BMI on clinical severity in patients with FM is still controversial. The aim of this study was to analyse the relationships between BMI categories and measures of symptom severity and functional impairment using data from a Web-based registry of patients with FM. Methods Adult patients with an ACR 2010/2011 diagnosis of FM underwent a complete physical examination and laboratory tests and were asked to complete a package of questionnaires covering their sociodemographic and treatment details, in addition to the following disease-specific questionnaires: the rev…

medicine.medical_specialtyobesityCross-sectional studyRevised Fibromyalgia Impact QuestionnaireOverweightNO03 medical and health sciencesBMI0302 clinical medicineRheumatologyInternal medicineFibromyalgiamedicineLS4_5030212 general & internal medicine030203 arthritis & rheumatologybusiness.industrymedicine.diseaseObesityDistressclinical severitywidespread painOriginal ArticlefibromyalgiaUnderweightmedicine.symptomAcademicSubjects/MED00010businessBody mass indexBMI; clinical severity; fibromyalgia; obesity; widespread pain
researchProduct

H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome

2017

Summary Macrophage activation syndrome (MAS) is hyperinflammatory life-threatening syndrome, associated typically with high levels of serum ferritin. This is an iron storage protein including heavy (H) and light (L) subunits, categorized on their molecular weight. The H-/L subunits ratio may be different in tissues, depending on the specific tissue and pathophysiological status. In this study, we analysed the bone marrow (BM) biopsies of adult MAS patients to assess the presence of: (i) H-ferritin and L-ferritin; (ii) CD68+/H-ferritin+ and CD68+/L-ferritin+; and (iii) interleukin (IL)-1β, tumour necrosis factor (TNF) and interferon (IFN)-γ. We also explored possible correlations of these re…

0301 basic medicineBiopsymedicine.medical_treatment0302 clinical medicineBone MarrowcytokineImmunology and AllergyInterleukinBlood ProteinsSyndromeMiddle AgedC-Reactive ProteinCytokinemedicine.anatomical_structureCytokinesTumor necrosis factor alphaInflammation Mediatorsmedicine.symptommacrophage activation syndromeAdultImmunologyAntigens Differentiation MyelomonocyticInflammationmacrophageBiologyProinflammatory cytokine03 medical and health sciencesAntigens CDmedicineHumansAgedRetrospective StudiesInflammation030203 arthritis & rheumatologyMacrophagesferritinOriginal ArticlesMacrophage Activationmedicine.diseaseFerritinSettore MED/16 - Reumatologia030104 developmental biologyMacrophage activation syndromeApoferritinsImmunologybiology.proteinBone marrowCytokine; Ferritin; Hyperferritinaemic syndrome; Macrophage; Macrophage activation syndrome; Immunology and Allergy; Immunologycytokine; ferritin; hyperferritinaemic syndrome; macrophage; macrophage activation syndromehyperferritinaemic syndrome
researchProduct

Erratum to “Is minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren’s syndrome? Association between clinical, histopathologica…

2015

Pathologymedicine.medical_specialtyAnesthesiology and Pain MedicineS syndromeRheumatologybusiness.industryMedicineArthritisRetrospective cohort studySalivary gland biopsybusinessmedicine.diseaseRheumSeminars in Arthritis and Rheumatism
researchProduct

Interstitial lung disease in systemic sclerosis: current and future treatment.

2017

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc–ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis,…

0301 basic medicinemedicine.medical_specialtyPathologyFibrosiImmunologyInterstitial lung diseaseSclerodermaPulmonary function testingSclerodermaPathogenesis03 medical and health sciencesSystemic sclerosi0302 clinical medicineRheumatologyFibrosisPredictive Value of TestsRisk FactorsInternal medicineCase fatality ratemedicineAnimalsHumansImmunology and AllergyMolecular Targeted Therapyskin and connective tissue diseasesLungCause of death030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryInterstitial lung diseaseHematopoietic Stem Cell Transplantationrespiratory systemmedicine.diseaseRheumatologyRespiratory Function Testsrespiratory tract diseasesTreatmentSettore MED/16 - Reumatologia030104 developmental biologyEarly DiagnosisTreatment OutcomebusinessLung Diseases InterstitialTomography X-Ray ComputedImmunosuppressive AgentsLung Transplantation
researchProduct

Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies

2015

In recent years, mesenchymal stromal cells (MSCs) have been largely investigated and tested as a new therapeutic tool for several clinical applications, including the treatment of different rheumatic diseases. MSCs are responsible for the normal turnover and maintenance of adult mesenchymal tissues as the result of their multipotent differentiation abilities and their secretion of a variety of cytokines and growth factors. Although initially derived from bone marrow, MSCs are present in many different tissues such as many peri-articular tissues. MSCs may exert immune-modulatory properties, modulating different immune cells in both in vitro and in vivo models, and they are considered immune-…

AdultCancer ResearchpathogenesiCellular differentiationImmunologyCell- and Tissue-Based TherapyBone Marrow CellsMesenchymal Stem Cell TransplantationRegenerative MedicineRegenerative medicineAutoimmune DiseaseAutoimmune DiseasesChondrocytesImmune systemIn vivoBone MarrowRheumatic DiseasesmedicineHumansImmunology and Allergyrheumatic diseaseGenetics (clinical)TransplantationOsteoblastsMesenchymal Stromal Cellbusiness.industryOsteoblastMesenchymal stem cellMesenchymal Stem CellsCell DifferentiationCell BiologyChondrocyteClinical trialmedicine.anatomical_structureregenerative therapyOncologymesenchymal stromal cells; pathogenesis; regenerative therapy; rheumatic disease; Adult; Autoimmune Diseases; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell- and Tissue-Based Therapy; Chondrocytes; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stromal Cells; Osteoblasts; Regenerative Medicine; Rheumatic DiseasesImmunologyBone Marrow CellBone marrowStem cellbusinessHuman
researchProduct

Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database

2021

ObjectiveThe role of age in influencing the severity of fibromyalgia (FM) is still controversial. The aim of this study is to define the contribution of age in the severity of FM from data from a large national database.MethodsThis cross-sectional study included adult patients with FM diagnosed according to the 2010/2011 American College of Rheumatology criteria. Disease severity was assessed with the revised Fibromyalgia Impact Questionnaire (FIQR) and the modified Fibromyalgia Assessment Status (FAS 2019mod). Patients were grouped into five age categories (between 18-40 years, between 41- 50 years, between 51-60 years, between 61-70 years, and =71 years). Differences in disease severity b…

AdultMaleSettore MED/16 - REUMATOLOGIAAdolescentImmunologyReproducibility of ResultsMiddle AgedFAS 2019mod.Severity of Illness IndexYoung AdultCross-Sectional StudiesRheumatologyagenational databaseSurveys and QuestionnairesQuality of LifeImmunology and AllergyHumansdisease severityFemalefibromyalgiaFIQR
researchProduct

Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.

2014

OBJECTIVE: The aim of this study was to evaluate the role of rituximab (RTX) in modulating the expression of the IL-17/IL-23 pathway in the salivary glands (SGs) of patients with primary SS (pSS). METHODS: Consecutive SG biopsies were obtained from 15 patients with pSS before and after 1 year of RTX therapy. The SG expression of IL-17, IL-23p19 and p-STAT3 was evaluated by immunohistochemistry at baseline and after RTX therapy. The role of mast cells in pSS patients in modulating the Th17 response and the immunologic effect of RTX on mast cells were also studied in in vitro experiments. RESULTS: IL-17 was overexpressed in the SGs of patients with pSS mainly by infiltrating T cells and mast …

AdultMaleSTAT3 Transcription FactorSjogren SyndromeApoptosisIn Vitro TechniquesInterleukin-23Peripheral blood mononuclear cellSalivary GlandsAntibodies Monoclonal Murine-DerivedRheumatologystomatognathic systemSettore BIO/13 - Biologia ApplicataBiopsyHumansMedicinePharmacology (medical)Mast CellsAgedmedicine.diagnostic_testbusiness.industryInterleukinsInterleukin-17IL17Middle AgedMast cellIn vitroSettore MED/16 - ReumatologiaSjogren's SyndromeTreatment Outcomemedicine.anatomical_structureApoptosisAntirheumatic AgentsImmunologyTh17 CellsImmunohistochemistryFemaleRituximabInterferonsInterleukin 17businessRituximabSignal Transductionmedicine.drug
researchProduct

Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study.

2017

Abstract Although the better management of rheumatoid arthritis (RA) has significantly improved the long-term outcome of affected patients, a significant proportion of these may develop associated comorbidities including cardiometabolic complications. However, it must be pointed out that a comprehensive cardiometabolic evaluation is still poorly integrated into the management of RA patients, due to a limited awareness of the problem, a lack of appropriate clinical studies, and optimal strategies for cardiovascular (CV) risk reduction in RA. In addition, although several studies investigated the possible association between traditional CV risk factors and RA, conflicting results are still av…

Blood GlucoseMalerheumatoid arthritisTime FactorsCross-sectional studyType 2 diabetesAdrenal Cortex HormoneBody Mass IndexArthritis Rheumatoid0302 clinical medicineimpaired fasting glucoseAdrenal Cortex HormonesRisk FactorsRheumatoidCardiovascular DiseasePrevalence030212 general & internal medicineMedicine (all)Diabetes MellituGeneral MedicineMiddle AgedC-Reactive ProteinCholesterolcardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes;Cardiovascular DiseasesCohortHypertensionFemaletype 2 diabetesCase-Control Studiecardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes; Adrenal Cortex Hormones; Adult; Aged; Arthritis Rheumatoid; Blood Glucose; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glucose Intolerance; Humans; Hypertension; Male; Middle Aged; Prevalence; Risk Factors; Time Factors; Medicine (all)Type 2Research ArticleArthritiHumanAdultcardiovascular riskmedicine.medical_specialtyTime FactorObservational StudyNO03 medical and health sciencesInternal medicineDiabetes mellitusGlucose Intolerancemedicinecardiovascular risk impaired fasting glucose inflammation rheumatoid arthritis type 2 diabetesHumansAged030203 arthritis & rheumatologyCross-Sectional Studietype 2 diabetebusiness.industryRisk Factor6900Case-control studyrheumatoid arthritimedicine.diseaseImpaired fasting glucoseSettore MED/16 - ReumatologiaCross-Sectional StudiesDiabetes Mellitus Type 2inflammationCase-Control StudiesMetabolic syndromebusinessBody mass index
researchProduct

Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers

2016

Background: Adult-onset Still's disease (AOSD) is rare inflammatory disease of unknown etiology that usually affects young adults. The more common clinical manifestations are spiking fevers, arthritis, evanescent rash, elevated liver enzymes, lymphadenopathy, hepatosplenomegaly, and serositis. The multi-visceral involvement of the disease and the different complications, such as macrophage activation syndrome, may strongly decrease the life expectancy of AOSD patients. Methods: This study aimed to identify the positive and negative features correlated with the outcome of patients. A retrospective analysis of AOSD patients prospectively admitted to three rheumatologic centers was performed t…

AdultMale0301 basic medicinemedicine.medical_specialtyPrognosiHepatosplenomegalyArthritisDiseaseAdult-onset Still's diseaseYoung Adult03 medical and health sciencesSystemic score0302 clinical medicineRetrospective StudieInternal medicinemedicineHumansYoung adultRetrospective StudiesAdult-onset Still’s diseaseMedicine(all)030203 arthritis & rheumatologyPrognostic factorbusiness.industryMedicine (all)BiomarkerGeneral MedicineMiddle AgedPrognosismedicine.diseaseRashSurgerySettore MED/16 - Reumatologia030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeEtiologyAdult-onset Still’s disease; Macrophage activation syndrome; Prognostic factor; Systemic scoreFemalemedicine.symptombusinessStill's Disease Adult-OnsetSerositisBiomarkersHumanResearch ArticleBMC Medicine
researchProduct

FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome

2017

Background During macrophage activation syndrome (MAS), an inflammatory life-threatening syndrome, extremely high levels of serum ferritin may be observed [1]. Ferritin is an intracellular iron storage protein comprising 24 subunits that may be divided in heavy (H) subunits and light (L) subunits, based on their molecular weight [2]. The H-/L-subunits ratio may change, depending on the specific tissue and the physiologic status of the cell. In the normal condition, ferritin enriched in L subunits (L-ferritin) has been found in the liver and in the spleen, whereas the ferritin enriched in H subunits (H-ferritin), may be mainly observed in the heart and kidneys [2]. Objectives We investigated…

medicine.medical_specialtybiologymedicine.diagnostic_testbusiness.industryCD68Spleen030204 cardiovascular system & hematologyProinflammatory cytokineFerritin03 medical and health sciences0302 clinical medicineEndocrinologymedicine.anatomical_structureWestern blotInternal medicineImmunologymedicinebiology.proteinMacrophageTumor necrosis factor alpha030212 general & internal medicineBone marrowbusinessPoster Presentations
researchProduct

Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS

2013

Bariatric surgery represents a common approach for the control of severe morbid obesity, reducing caloric intake by modifying the anatomy of the gastrointestinal tract. Following jejunoileal bypass, a large spectrum of complications has been described, with rheumatic manifestation present in up to 20% of cases. Although bowel bypass syndrome, also called blind loop syndrome, is a well-recognized complication of jejunoileal bypass, the same syndrome was recognized in patients who had not had intestinal bypass surgery, and the term the 'bowel-associated dermatosis-arthritis syndrome' (BADAS) was coined. The pathogenesis of BADAS is as yet poorly understood and only few data concerning this is…

Short Bowel Syndromemedicine.medical_specialtyPediatricsmedicine.medical_treatmentJejunoileal bypass immune-related conditionsImmunologyJejunoileal bypassSkin DiseasesGastroenterologyImmune systemBlind loop syndromeJejunoileal BypassInternal medicinemedicineHumansImmunology and AllergyIn patientIntestinal bypassbusiness.industryBowel-associated dermatosis–arthritis syndromeArthritismedicine.diseaseCaloric intakeimmune-related conditionsBlind Loop SyndromeComplicationbusinessJejunoileal bypa
researchProduct

Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with…

2015

The aim of this study was to assess safety and efficacy of ultrasonography (US)-guided intra-articular injections using tumor necrosis factor (TNF) blockers compared to corticosteroids in rheumatoid arthritis (RA) or psoriatic arthritis (PsA) patients, experiencing refractory monoarthritis despite the current systemic therapy. Eighty-two patients were randomized to receive three intra-articular injections monthly of either corticosteroid or TNF blockers. Primary endpoints were the safety and an improvement greater than 20% for visual analogic scales of involved joint pain in patients injected with anti-TNFα. Further clinical, US, and magnetic resonance imaging (MRI) evaluations were consid…

0301 basic medicineMalerheumatoid arthritispsoriatic arthritimagnetic resonance imaging (MRI)anti-tumor necrosis factor α agent; intra-articular injection; magnetic resonance imaging (MRI); psoriatic arthritis; rheumatoid arthritis; treat-to-target strategy; ultrasonography; Pharmacology; Immunology; Immunology and AllergyInflammatory arthritisAnti-Inflammatory Agentsanti-tumor necrosis factor α agentInjections Intra-ArticularArthritis Rheumatoid0302 clinical medicineAdrenal Cortex HormonesImmunology and Allergyintra-articular injectionpsoriatic arthritismedicine.diagnostic_testultrasonographyMiddle AgedArthralgiaRheumatoid arthritisJoint painAntirheumatic AgentsCorticosteroidTumor necrosis factor alphaFemalemedicine.symptomAdultmedicine.medical_specialtymedicine.drug_classImmunology03 medical and health sciencesPsoriatic arthritisInternal medicineMonoarthritismedicineHumansImmunologic FactorsAged030203 arthritis & rheumatologyPharmacologybusiness.industryTumor Necrosis Factor-alphaArthritis PsoriaticMagnetic resonance imagingOriginal Articlesrheumatoid arthritimedicine.diseaseSurgerytreat-to-target strategy030104 developmental biologybusiness
researchProduct

FRI0504 Prognostic Factors of Adult Onset Still's Disease: Analysis of 100 Cases in 3 Tertiary Referral Centers

2016

Background Adult onset Still9s disease (AOSD) is rare inflammatory disease [1]. Three different patterns of AOSD have been identified: i. monocyclic pattern, characterized by a systemic single episode; ii. polycyclic pattern, associated with multiple flares, separated by remissions; iii. chronic pattern, related to a persistently active disease with associated polyarthritis [2]. Until now, the treatment of AOSD remains largely empirical, lacking controlled clinical trials [1]. Objectives We aimed to investigate clinical data of AOSD patients and any possible correlation among these features and the outcome of patients. Methods Clinical data of 100 AOSD patients were recorded. All patients f…

medicine.medical_specialtyImmunologyArthritisGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTocilizumabRheumatologyInternal medicinemedicineImmunology and Allergy030212 general & internal medicine030203 arthritis & rheumatologyAnakinramedicine.diagnostic_testbusiness.industrymedicine.diseaseRashSurgerychemistryErythrocyte sedimentation rateMacrophage activation syndromePolyarthritismedicine.symptombusinessComplicationmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission.…

2019

Abstract To assess the effectiveness of the treatment with high dosage of corticosteroids (CCSs), as first-line therapy, in inducing remission in naïve Adult-onset Still's disease (AOSD) patients compared with low dosage of CCSs, after 6 months. To further evaluate the rate of patients maintaining the remission and the rate of CCSs discontinuation, after additional 12 months of follow-up. A retrospective evaluation of patients prospectively followed was designed to compare the rate of clinical remission in naïve AOSD patients treated with high dosages of CCSs (0.8–1 mg/kg/day of prednisone-equivalent) or low dosage of CCSs (0.2–0.3 mg/kg/day of prednisone-equivalent), after 6 months. An add…

Adult-OnsetMalePediatricsAdult-onset Still's diseaseDiseaseAdrenal Cortex Hormonecorticosteroids0302 clinical medicinemonocyclic patternAdrenal Cortex HormonesRetrospective StudieMedicine030212 general & internal medicineProspective StudiesProspective cohort studyRemission InductionDisease ManagementGeneral MedicineMiddle AgedTreatment OutcomeHigh dosage030220 oncology & carcinogenesisFemaleDrugStill's Disease Adult-OnsetResearch ArticleHumanAdultcorticosteroidmedicine.medical_specialtyLow dosageObservational StudyAdult-onset Still's diseaseFollow-Up StudieDose-Response Relationship03 medical and health sciencesremissionAdult-onset Still's disease; corticosteroids; first-line therapy; monocyclic pattern; remission; Adrenal Cortex Hormones; Adult; Disease Management; Dose-Response Relationship Drug; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Remission Induction; Retrospective Studies; Still's Disease Adult-Onset; Treatment Outcomefirst-line therapyHumansRetrospective StudiesDose-Response Relationship Drugbusiness.industry6900Retrospective cohort studyStill's DiseaseFirst line treatmentSettore MED/16 - ReumatologiaProspective StudieMethotrexateObservational studybusinessFollow-Up Studies
researchProduct

IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

2016

ABSTRACT: Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are affected by Type 2 Diabetes (T2D), whose incidence has reached epidemic levels in recent years, thus increasing the health care costs. A better knowledge about the pathogenesis of these diseases as well as the mechanisms of action of drugs may allow both policy designers and physicians to choose the most effective treatments, thus lowering the costs. This review will focus on the role of Interleukin (IL)-1β in the pathogenesis of …

0301 basic medicinemedicine.medical_specialtyIL-1 blocking agentpathogenesimedicine.medical_treatmentInterleukin-1betaImmunologyType 2 diabetesComorbiditymacrophagePathogenesisArthritis Rheumatoid03 medical and health sciencesHealth careMedicineAnimalsHumansImmunology and AllergyRheumatoid arthritisIntensive care medicineAntibodies BlockingRheumatoid arthrititype 2 diabetebusiness.industryIL-1 blocking agentsIncidence (epidemiology)pathogenesisInterleukinImmunotherapybiologic drug; IL-1 blocking agents; IL-1β; macrophage; pathogenesis; Rheumatoid arthritis; type 2 diabetes; Immunology and Allergy; Immunologymedicine.diseaseComorbiditySettore MED/16 - Reumatologia030104 developmental biologyDiabetes Mellitus Type 2IL-1βRheumatoid arthritisImmunologyImmunotherapytype 2 diabetesbusinessbiologic drug
researchProduct

Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?

2017

Introduction: Macrophage activation syndrome (MAS) is a severe, hyperinflammatory life-threatening syndrome, generally complicating different rheumatic diseases. Despite the severity of the disease, little is known about the pathogenic mechanisms and, thus, possible targeted therapies in the management of these patients. Areas covered: In this review, we aimed to update the current pathogenic knowledge of MAS, during rheumatic diseases, focusing mainly on immunologic abnormalities and on new possible therapeutic strategies. Expert commentary: The difficult pathogenic scenario of MAS, in which genetic defects, predisposing diseases, and triggers are mixed together with the high mortality rat…

adult onset Still’s disease0301 basic medicineAdultAdult-onset Still's diseasemedicine.medical_treatmentImmunologyInflammationmacrophagemacromolecular substancesDisease03 medical and health sciences0302 clinical medicineRheumatic DiseasescytokinemedicineImmunology and AllergyMacrophageAnimalsHumanssystemic juvenile idiopathic arthritiMolecular Targeted TherapyChildExpert Testimony030203 arthritis & rheumatologyInflammationbusiness.industrymusculoskeletal neural and ocular physiologyMacrophage Activation Syndromehyperferritinemic syndromeMacrophage Activationmedicine.diseaseSettore MED/16 - Reumatologia030104 developmental biologyCytokinenervous systemMacrophage activation syndromeImmunologymedicine.symptombusinessExpert review of clinical immunology
researchProduct

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers

2016

Background Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome [1]. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokines storm the latter contributing to the development of multi-organ failure [2]. Objectives In the current study, we aimed to investigate clinical data, treatments, and outcome of adult MAS patients secondary to autoimmune rheumatic disease. Methods We retrospectively investigated clinical data, treatments, and outcome of 40 adult MAS patients secondary to autoimmune rheumatic disease…

medicine.medical_specialtyImmunologyCatastrophic antiphospholipid syndromeGastroenterologyGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundTocilizumabRheumatologyInternal medicinemedicineImmunology and AllergyMacrophage activation syndrome adult onset Still‟s disease hyperferritinemic syndromebusiness.industrySeptic shockProportional hazards modelMortality ratehyperferritinemic syndromeadult onset Still‟s diseasemedicine.diseaseComorbiditySurgeryMethylprednisolonechemistryMacrophage activation syndromeMacrophage activation syndromebusinessmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients

2021

Abstract Objective To establish optimal cut-off values for the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromialgia Assessment Scale (FAS 2019mod), and the Polysymptomatic Distress Scale (PDS) in order to distinguish five levels of FM disease severity. Methods Consecutive FM patients were evaluated with the three clinimetric indices, and each patient was required to answer the anchor question: ‘In general, would you say your health is 1 = very good, 2 = good, 3 = fair, 4 = poor, or 5 = very poor?’—which represented the external criterion. Cut-off points were established through the interquartile reconciliation approach. Results The study sample consisted…

MalePercentileSettore MED/16 - REUMATOLOGIAFibromyalgiaCross-sectional studyseverityDiseaseSeverity of Illness IndexEconomica0302 clinical medicinemodifiedInterquartile rangeRetrospective StudieFibromyalgiaSurveys and QuestionnairesSurveys and QuestionnairePharmacology (medical)030212 general & internal medicinecut-off pointsPain MeasurementFibromyalgia Assessment Status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severity; Cross-Sectional Studies; Female; Fibromyalgia; Follow-Up Studies; Humans; Incidence; Italy; Male; Middle Aged; Pain Measurement; Prognosis; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of LifeIncidencerevised Fibromyalgia Impact Questionnairecut-off points; fibromyalgia; Fibromyalgia Assessment Status; modified; polysymptomatic distress scale; revised Fibromyalgia Impact Questionnaire; severityMiddle AgedPrognosisDistressItalyFemalefibromyalgiaFibromyalgia Assessment StatusHumanmedicine.medical_specialtyPrognosiRevised Fibromyalgia Impact QuestionnaireFollow-Up Studie03 medical and health sciencesRheumatologyInternal medicineSeverity of illnesscut-off pointmedicineHumansRetrospective Studies030203 arthritis & rheumatologyCross-Sectional Studiebusiness.industrymedicine.diseaseFibromyalgia Assessment StatuCross-Sectional StudiesFibromyalgia; severity; cut-off points; revised Fibromyalgia Impact Questionnaire; modified; Fibromyalgia Assessment Status; polysymptomatic distress scalepolysymptomatic distress scalefibromyalgia assessment status; cut-off points; fibromyalgia; modified; polysymptomatic distress scale; revised fibromyalgia impact questionnaire; severityQuality of LifebusinessFollow-Up Studies
researchProduct

AB0630 Cardiac Magnetic Resonance Imaging with Pharmacological Stress Perfusion in Asymptomatic Patients with Systemic Sclerosis

2016

Background Systemic Sclerosis (SSc)-heart disease (SSc-HD), although often clinically silent, significantly reduces the life-expectancy in these patients [1]. The cardiac magnetic resonance (CMR) is recognized useful tool for the diagnosis of SSc-HD and cardiac stress tests might be a helpful technique to highlight the occult myocardial involvement, which cannot be detected at rest due to compensatory mechanisms [2,3]. Objectives To evaluate the possible occult cardiac involvement in asymptomatic SSc patients by pharmacological stress, rest perfusion and delayed enhancement CMR, to identify as earlier as possible those patients at higher risk of cardiac related mortality and needing specifi…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryImmunologyArthritismedicine.diseaseAsymptomaticGeneral Biochemistry Genetics and Molecular BiologyRheumatologyCoronary arteriesmedicine.anatomical_structureRheumatologyCardiac magnetic resonance imagingVentricleInternal medicineImmunology and AllergyMedicineRadiologymedicine.symptombusinessPerfusionRheumatismAnnals of the Rheumatic Diseases
researchProduct

Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic scler…

2017

Objective To evaluate occult cardiac involvement in asymptomatic systemic sclerosis (SSc) patients by pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance (CMR), for a very early identification of patients at higher risk of cardiac-related mortality. Methods Sixteen consecutive patients with definite SSc, fulfilling the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria in less than 1 year from the onset of Raynaud's phenomenon, underwent pharmacological stress, rest perfusion and delayed enhancement CMR. At enrollment, no patient showed signs and/or symptoms suggestive for cardiac involvement. No patient sho…

AdultMalemedicine.medical_specialtyAdenosineHeart diseaseHeart DiseasesVasodilator AgentsContrast MediaMagnetic Resonance Imaging CineAsymptomaticCardiac magnetic resonance imaging with pharmacological stress; Myocardial perfusion defect; Systemic sclerosis; Systemic sclerosis heart involvement; Rheumatology030218 nuclear medicine & medical imaging03 medical and health sciencesMyocardial perfusion imagingCoronary circulation0302 clinical medicineRheumatologyPredictive Value of TestsInternal medicineCoronary CirculationCardiac magnetic resonance imaging with pharmacological stressMultidetector Computed TomographymedicineHumans030203 arthritis & rheumatologyScleroderma Systemicmedicine.diagnostic_testbusiness.industryMicrocirculationMyocardial Perfusion Imagingmedicine.diseaseRheumatologymyocardial perfusion defectSettore MED/16 - Reumatologiamedicine.anatomical_structureEarly DiagnosisVentriclecardiac magnetic resonance imaging with pharmacological streAsymptomatic Diseasessystemic sclerosis heart involvementSystemic sclerosisFemaleRadiologymedicine.symptombusinessPerfusionsystemic sclerosiRheumatism
researchProduct

Cardiovascular disease in primary sjögren’s syndrome

2018

Background A close relationship between rheumatic diseases and cardiovascular disease (CVD) has been reported, accounting for the higher mortality and morbidity observed in these patients. In the last years, it has been clearly reported that patients affected by primary Sjogren's syndrome (pSS) experienced an increased risk of CVD. Objective This review aimed at investigating CVD, traditional cardiovascular (CV) risk factors and possible targeted therapeutic strategies in pSS patients. Method Available literature concerning CV risk factors in pSS patients has been selected and discussed. Conclusion Disease-related characteristics and traditional CV risk factors contribute to observed athero…

medicine.medical_specialtyFuture studiesEndothelial damageDiseaseType 2 diabetesComorbidity030204 cardiovascular system & hematologySjögren syndrome03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineMedicineHumans030212 general & internal medicinePharmacologybusiness.industryRisk FactorGeneral Medicinemedicine.diseaseAtherosclerosisCardiovascular diseaseCardiovascular riskComorbiditySjögren syndromestomatognathic diseasesSettore MED/16 - ReumatologiaAtherosclerosis; Cardiovascular disease; Cardiovascular risk; Comorbidity; Endothelial damage; Sjögren syndrome; PharmacologyIncreased riskSjogren's SyndromeClose relationshipCardiovascular DiseasesAtherosclerosiSjogren sbusinessHuman
researchProduct

Rituximab in primary Sjögren's syndrome: a ten-year journey

2014

Primary Sjögren's syndrome (pSS) is an autoimmune disorder affecting exocrine glands and characterized in most cases by a rather mild clinical picture. However, a subgroup of pSS patients experience systemic extraglandular involvement leading to a worsening of disease prognosis. Current therapeutic options for the treatment of pSS are mainly empirical, often translated by other autoimmune diseases, and recent systematic reviews have highlighted the lack of evidence-based recommendations for most of the drugs commonly employed in the spectrum of extraglandular involvement. Because of the well-established role of B-lymphocytes in the pathogenesis of pSS, a B-cell targeting therapy may repres…

Oncologymedicine.medical_specialtySjogren's syndrome RituximabContext (language use)DiseasePathogenesisAntibodies Monoclonal Murine-DerivedTherapeutic approachRheumatologyInternal medicinemedicineHumansImmunologic FactorsLymphocyte CountClinical efficacyB-Lymphocytesbusiness.industrystomatognathic diseasesSystematic reviewSjogren's syndromeImmunologyRituximabSjogren sbusinessRituximabmedicine.drug
researchProduct

Advancing frontiers in rheumatic and musculoskeletal imaging.

2021

AbstractIn recent years, technological improvements allowed imaging modalities to become increasingly essential in achieving early and precise diagnoses in the field of rheumatic and musculoskeletal diseases (RMDs). To date, imaging examinations are routinely used in all steps of diagnostic and therapeutic care pathways of patients affected by RMDs. The articles published in this Article Collection clearly show the efforts of researchers to find innovative applications of musculoskeletal imaging in clinical practice and to face the crucial challenges that remain in the interpretation and quality control of images. Highly performing diagnostic technologies are currently available to early di…

medicine.medical_specialtylcsh:Diseases of the musculoskeletal systemImaging modalitiesRheumatologyMedicineHumansOrthopedics and Sports MedicineMedical physicsMusculoskeletal DiseasesMedical diagnosisRadionuclide ImagingMusculoskeletal imagingUltrasonographyShear wave elastographyMusculoskeletal imagingModalitiesbusiness.industryComputed tomography: magnetic resonance imagingPrecision medicineMagnetic Resonance ImagingClinical PracticeEditorialShear wave elastographyElasticity Imaging Techniqueslcsh:RC925-935businessBMC musculoskeletal disorders
researchProduct

Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 case…

2016

Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significan…

AdultMalemusculoskeletal diseases0301 basic medicinemedicine.medical_specialtyImmunologyAdult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome; Adult; Ambulatory Care Facilities; Autoimmune Diseases; Female; Humans; Immunosuppressive Agents; Macrophage Activation Syndrome; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Immunology and Allergy; ImmunologyDiseaseAmbulatory Care FacilitiesAutoimmune Diseases03 medical and health sciences0302 clinical medicineAdult onset Still's diseaseInternal medicineHumansImmunology and AllergyMedicineRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseaseAdult patientsbusiness.industryMortality ratefungiRetrospective cohort studyMiddle AgedPrognosisHyperferritinemic syndromemedicine.diseasebody regionsSettore MED/16 - ReumatologiaTreatment Outcome030104 developmental biologyMacrophage activation syndromeMacrophage activation syndromeCohortImmunologyFemalelipids (amino acids peptides and proteins)businessCytokine stormImmunosuppressive Agentshormones hormone substitutes and hormone antagonistsAutoimmunity Reviews
researchProduct

Is minor salivary gland biopsy more than a diagnostic tool in primary Sjorgren's syndrome? Association between clinical, histopathological, and molec…

2014

Objectives: Several histological scoring systems, including the focus score, performed in minor salivary glands (MSGs) by hematoxylin-eosin (H&E) staining, have been employed in clinical practice to assess the inflammatory infiltrate and provide the diagnosis of primary Sjorgren's syndrome (pSS). Aims of this study were to integrate different scoring systems and identify potential differences in the molecular profile of lymphoid cytokines related to germinal center (GC) formation and clinical subsets in pSS. Methods: Overall, 104 pSS patients and 40 subjects with sicca non-pSS were retrospectively evaluated. MSG biopsies were evaluated by H&E and immunofluorescence to assess histological pa…

MalePathologyT-LymphocytesBiopsyRetrospective Studiesalivary glands biopsyB-Lymphocytesmedicine.diagnostic_testbiologyLTαLTβMedicine (all)HypergammaglobulinemiaB-LymphocyteCXCL13CXCL12Middle AgedSjogren's syndrome salivary glands biopsySjogren's SyndromeCytokinesBAFFFemaleAntibodyHumanmusculoskeletal diseasesAdultmedicine.medical_specialtyBAFF; CCL19; CCL21; CCR7; CXCL12; CXCL13; CXCR4; CXCR5; Germinal center; LTα; LTβ; Minor salivary glands; Sjorgren's syndrome; Adult; B-Lymphocytes; Biomarkers; Biopsy; Cytokines; Female; Germinal Center; Humans; Male; Middle Aged; Retrospective Studies; Salivary Glands Minor; Sjogren's Syndrome; T-Lymphocytes; Rheumatology; Anesthesiology and Pain Medicine; Medicine (all)ImmunofluorescenceSalivary Glands MinorSalivary Glandstomatognathic systemRheumatologyInternal medicineBiopsyCCL19medicineHumansCXCL13B-cell activating factorCytokineRetrospective StudiesCXCR4Minor salivary glandbusiness.industryRetrospective cohort studyGerminal centerBiomarkermedicine.diseaseeye diseasesRheumatologyCXCR5Minorstomatognathic diseasesAnesthesiology and Pain MedicineT-LymphocyteSjorgren's syndromebiology.proteinbusinessBiomarkersCCL21CCR7
researchProduct

AB0919 H-Ferritin and CD68+/H-ferritin+ Cells Are Increased in The Skin of Adult Onset Still's Disease Patients and Correlate with The Disease Activi…

2016

Background Adult onset Still9s disease (AOSD) is an inflammatory disease, characterized by high spiking fevers, arthritis, salmon-pink erythema and multivisceral involvement [1]. During AOSD, exceptionally high serum levels of ferritin may be observed and they might contribute to production of proinflammatory molecules [2]. Ferritin is composed by 24 subunits, heavy (H) subunits and light (L) subunits. The ferritin enriched in L subunits (L-ferritin) and the ferritin enriched in H subunits (H-ferritin) may be recognized in different tissues [3]. Objectives To investigate the skin tissue expression of both H-and L-ferritin and the number of macrophages expressing these molecules, in the infl…

0301 basic medicineErythemabiologyCD68Septic shockbusiness.industryImmunologyArthritismedicine.disease_causemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyAutoimmunityProinflammatory cytokineFerritin03 medical and health sciences030104 developmental biologyRheumatologyMacrophage activation syndromeImmunologymedicinebiology.proteinImmunology and Allergymedicine.symptombusinessAnnals of the Rheumatic Diseases
researchProduct

Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome

2012

We have recently demonstrated that interleukin (IL)-22, mainly produced by T-helper 17 effector cells, natural killer (NK)p44+NK cells and epithelial cells, may be potentially involved in the pathogenesis of primary Sjogren's syndrome (pSS).1 The IL-22/IL-22R pathway is known to play a role in the emergence of T and B-cell lymphoma2 ,3 and pSS is considered a risk factor for the development of lymphoma.4 Rituximab, which has historically been used for the treatment of B-cell lymphoma,5 has also been considered to be effective in the therapy of pSS.6 Ten consecutive patients with pSS (eight women and two men, with a mean duration of disease of 48±18 months), diagnosed according to the Americ…

biologybusiness.industryImmunologyInterleukinmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyLymphomaInterleukin 22Pathogenesissjogren's syndromestomatognathic diseasesRituximab sjogren's syndromeRheumatologyMonoclonalImmunologymedicinebiology.proteinImmunology and AllergyRituximabAntibodyRisk factorbusinessRituximabmedicine.drug
researchProduct

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.

2013

Introduction Primary Sjögren’s syndrome (pSS) is an autoimmune disorder affecting exocrine glands; however, a subgroup of pSS patients experience systemic extra-glandular involvement leading to a worsening of disease prognosis. Current therapeutic options are mainly empiric and often translated by other autoimmune diseases. In the last few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS. Patients with early active disease appear to be those who could benefit the most from RTX. The aim of this study was to investigate the efficacy and safety of RTX in comparison to disease modifying anti-rheumatic drugs (DMARDs) in early active pSS patients. …

AdultMaleReceptors CXCR5musculoskeletal diseasesReceptors CXCR4Salivamedicine.medical_specialtySjogren's syndrome RituximabTime FactorsBiopsyImmunologyGene ExpressionDiseaseSalivary GlandsAntibodies Monoclonal Murine-Derivedstomatognathic systemRheumatologyInternal medicineBiopsyHumansImmunology and AllergyMedicineProspective StudiesProspective cohort studyAdverse effectFatiguePain Measurementmedicine.diagnostic_testSalivary glandReverse Transcriptase Polymerase Chain Reactionbusiness.industryMiddle AgedChemokine CXCL13Chemokine CXCL12Rheumatologystomatognathic diseasesTreatment Outcomemedicine.anatomical_structureSjogren's syndromeAntirheumatic AgentsImmunologyFemaleRituximabSelf ReportRituximabbusinessFollow-Up StudiesResearch Articlemedicine.drug
researchProduct

The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular…

2015

Summary In this work, we aimed to evaluate the levels of ferritin enriched in H subunits (H-ferritin) and ferritin enriched in L subunits (L-ferritin) and the cells expressing these two molecules in the lymph node (LN) biopsies obtained from adult-onset Still's disease (AOSD) patients, and the possible correlation among these data and the severity of the disease. Ten patients with AOSD underwent LN biopsy. All the samples were stained by immunofluorescence. A statistical analysis was performed to estimate the possible correlation among both H-ferritin and L-ferritin tissue expression and the clinical picture of the disease. Furthermore, the same analysis was performed to evaluate the possib…

0301 basic medicineAdult-OnsetMalePathologyMacrophageApoferritinAdult-onset Still's disease; H-ferritin; Hyperferritinaemic syndrome; Macrophage; Adult; Aged; Antigens CD; Antigens Differentiation Myelomonocytic; Apoferritins; Biopsy; Female; Ferritins; Fluorescent Antibody Technique; Humans; Lymph Nodes; Macrophages; Male; Middle Aged; Still's Disease Adult-Onset; Immunology; Immunology and AllergyH-ferritinBiopsyFluorescent Antibody TechniquePathogenesis0302 clinical medicineMacrophageImmunology and AllergyLymph nodemedicine.diagnostic_testCD68Lymph NodeMiddle AgedCDmedicine.anatomical_structureAntigenDifferentiationFemaleLymphHyperferritinaemic syndromeStill's Disease Adult-OnsetHumanAdultmedicine.medical_specialtyImmunologyAntigens Differentiation MyelomonocyticBiologyImmunofluorescenceAdult-onset Still's disease03 medical and health sciencesAntigens CDBiopsymedicineHumansAntigensAged030203 arthritis & rheumatologyFerritinMacrophagesOriginal ArticlesMyelomonocyticStill's DiseaseFerritinSettore MED/16 - Reumatologia030104 developmental biologyImmunologyApoferritinsFerritinsbiology.proteinLymph Nodes
researchProduct

Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibrobla…

2018

Abstract Background Fibrosis may be considered the hallmark of systemic sclerosis (SSc), the end stage triggered by different pathological events. Transforming growth factor-β (TGF-β) and platelet-derived growth factor BB (PDGF-BB) are profibrotic molecules modulating myofibroblast differentiation and proliferation, respectively. There is evidence linking CD248 with these two molecules, both highly expressed in patients with SSc, and suggesting that CD248 may be a therapeutic target for several diseases. The aim of this work was to evaluate the expression of CD248 in SSc skin and its ability to modulate SSc fibrotic process. Methods After ethical approval was obtained, skin biopsies were co…

0301 basic medicineMalelcsh:Diseases of the musculoskeletal systemProton Pump InhibitorFibrosiCellular differentiationmedicine.medical_treatmentSystemic sclerosiFibrosisImmunology and AllergyMedicineMyofibroblastsskin and connective tissue diseasesCells CulturedSkinintegumentary systemCell DifferentiationMiddle AgedMesenchymal Stem CellBenzamidesSystemic sclerosisFemaleMyofibroblastResearch ArticleHumanAdultStromal cellImmunology03 medical and health sciencesYoung AdultRheumatologyBenzamideAntigens CDAntigens NeoplasmHumansGene silencingCell ProliferationMyofibroblastScleroderma Systemicbusiness.industryGrowth factorMesenchymal stem cellStromal CellMesenchymal Stem CellsProton Pump Inhibitorsmedicine.diseaseFibrosisCD248Settore MED/16 - Reumatologia030104 developmental biologyCancer researchStromal Cellslcsh:RC925-935CD248; Fibrosis; Systemic sclerosis; Rheumatology; Immunology and Allergy; ImmunologybusinessTransforming growth factor
researchProduct

The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes

2018

Background Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients. Objective We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process. Method After literature search, the available evidence has bee…

0301 basic medicineInterleukin-1betaInflammationAnakinra; Cardiovascular risk; Diabetes; IL-1β; Pathogenesis; Rheumatoid arthritis; Therapy; PharmacologyType 2 diabetesPathogenesisDiabeteProinflammatory cytokinePathogenesisArthritis Rheumatoid03 medical and health sciencesImmune systemPathogenesiDiabetes mellitusmedicineHumansRheumatoid arthritisRheumatoid arthritiPharmacologyAnakinrabusiness.industryDiabetesAntirheumatic AgentReceptors Interleukin-1General Medicinemedicine.diseaseCardiovascular riskSettore MED/16 - Reumatologia030104 developmental biologyAnakinraDiabetes Mellitus Type 2IL-1βRheumatoid arthritisAntirheumatic AgentsImmunologyTherapymedicine.symptombusinessmedicine.drugHuman
researchProduct

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct